Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

In Vivo and in Vitro Efficacy of the Recommended First Line Antimalarial Treatments (Artemether-Lumefantrine and Amodiaquine-Artesunate) in Children With Uncomplicated Malaria in Burkina Faso

NCT00808951 is registered in ClinicalTrials.gov with Centre Muraz as lead sponsor.

NCT NCT00808951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00808951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
In Vivo and in Vitro Efficacy of the Recommended First Line Antimalarial Treatments (Artemether-Lumefantrine and Amodiaquine-Artesunate) in Children With Uncomplicated Malaria in Burkina Faso
Lead sponsor
Centre Muraz
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2008
Completion date
February 28, 2011
Enrollment
440 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria